Abstract
We examined aminoglycoside (AG) resistance in ampicillin-resistant Escherichia coli obtained from nine hospitals participating in the National Nosocomial Infections Study. The isolates were tested to 25 antimicrobials using broth microdilution methods. If the organism was intermediate or resistant to gentamicin, tobramycin, netilmicin, or amikacin, we determined the class of aminoglycoside-modifying enzyme (AME) using the phosphocellulose paper binding assay. Of 423 E. coli, 21 (5%) were intermediate or resistant to one or more of the AGs. All but two of these E. coli isolates had at least one AME. Twelve isolates had phosphotransferase (APH) enzymes; seven had adenyltransferase (ANT) enzymes (all ANT[2"]); and four had acetyltransferase (AAC) enzymes. The seven ANT[2"]-producing isolates were more likely to be acquired in the community than in the hospital (4/7 ANT[2"]-producing E. coli versus one of 14 of the other AG-resistant E. coli, p = 0.03, Fisher's exact test). These findings suggest that for E. coli resistant to both ampicillin and an AG, APH enzymes are the predominant AME class. Additionally, isolates with certain AMEs may be acquired both in the community and in the hospital.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.